Shire drops Dynepo but raises revenue guidance
This article was originally published in Scrip
Executive Summary
Shireis to drop its anaemia treatment Dynepo (epoetin delta) after the drug performed poorly in the second quarter, earning just $7 million. Dynepo was launched in Europe in March last year but has continued to disappoint, making just $14 million last year and another $14 million in the first half of this year. Shire attributed the discontinuation to significant reductions in prices following the entry of bio-similars to the market. The company recorded charges of $150 million as a result of the move, but said that it would redirect its resources to the launches of products such as Mezavant (mesalazine) and Daytrana (methylphenidate transdermal system) in Europe.